Clinical trials: E.Coli Infections, active
Cervical Cancer, Condylomata Acuminata
Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women
This study is designed to compare plateau antibody levels of a novel recombinant human papillomavirus vaccine (types 6,11,16,18,31,33,45,52,58 )(E.Coli) manufactured by Xiamen Innovax Biotech CO., Ltd., with Gardasil®9 in females…
- Trial name
- NCT06197802
- Testing
- Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli), Gardasil®9
- Where
- China
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Escherichia Coli; Infection, Intestinal
Study of the Ecological and Evolutionary Dynamics of Escherichia Coli in the Digestive Commensal Flora
Escherichia coli (E. coli) poses a major public health problem. E. coli is not only a commensal of the digestive tract but also a major opportunistic pathogen, first cause of urinary tract infections, first cause of bacteremia.
- Trial name
- EVE (NCT05153824)
- Where
- 2 sites in France
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Antibiotic Resistance, Enterobacteriaceae Infections
Genomic and Phenotypic Diversity of Carbapenemase-producing Escherichia Coli Strains Circulating in Southern France
Carbapenemase-producing Enterobacteriaceae (CPE) are classified as emerging Highly Resistant Bacteria (eHRB) because they expose infected patients to the risk of treatment failure due to the strains' resistance to last-line…
- Conditions
- Antibiotic Resistance, Enterobacteriaceae Infections, Carbapenem-Resistant Enterobacteriaceae Infection, Colonization
- Trial name
- CARBACOLI (NCT07676513)
- Testing
- MultiLocus Sequence Typing
- Where
- France
- Volunteers
- 163 people
- Sponsor
- Centre Hospitalier Universitaire de Nīmes
Shiga Toxin-Producing Escherichia Coli (E. Coli) Infection, Hemolytic-Uremic Syndrome
Hyperhydration in Children With Shiga Toxin-Producing E. Coli Infection
The objective of this study is to determine if early high volume intravenous fluid administration (hyperhydration) may be effective in mitigating or preventing complications of shiga toxin-producing E.
- Trial name
- HIKO-STEC (NCT05219110)
- Testing
- Infusion of 200% maintenance fluids as balanced crystalloid IV solution, Oral fluids; infusion of up to 110% maintenance fluids as balanced crystalloid IV solution
- Where
- 26 sites in United States, Canada
- Volunteers
- 1,040 people
- Sponsor
- University of Calgary
Cervical Intraepithelial Neoplasia, Cervical Cancer
Efficacy, Immunogenicity and Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
This phase III clinical study was designed to evaluate the efficacy,immunogenicity and safety of Recombinant Human Papillomavirus Vaccine (6,11,16,18,31,33,45,52,58 Type)(E.Coli) manufactured by Xiamen Innovax Biotech CO., LTD.…
- Conditions
- Cervical Intraepithelial Neoplasia, Cervical Cancer, Condylomata Acuminata
- Trial name
- NCT04537156
- Testing
- Nonavalent HPV vaccine, Bivalent HPV vaccine
- Where
- 2 sites in China
- Volunteers
- 9,327 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Urinary Tract Infections
A Study on the Safety and Immune Response of a Urinary Tract Infection (UTI) Vaccine in Adults 18-64 Years of Age and Clinical Efficacy in Females 18-64 Years of Age
The purpose of this study is to assess safety, reactogenicity, and immune response of the candidate UTI vaccine compared to placebo in adults between and including 18-64 years of age (YOA), and to perform a preliminary evaluation…
- Trial name
- NCT06702449
- Testing
- Candidate UTI vaccine low dose formulation 1, Candidate UTI vaccine low dose formulation 2, Candidate UTI vaccine medium dose formulation 1
- Where
- 8 sites in United States, South Africa
- Volunteers
- 448 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Penile/Perineal /Perianal Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia
A Phase III Trial to Evaluate the Efficacy, Immunogenicity and Safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) in Chinese Males
This phase III clinical trial was designed to evaluate the efficacy, immunogenicity and safety of a Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.Coli) manufactured by Xiamen…
- Conditions
- Penile/Perineal /Perianal Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia, Penile/Perianal/Perineal Cancer, Anal Cancer
- Trial name
- NCT06866574
- Testing
- Recombinant Human Papillomavirus 9-Valent (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) Vaccine (E.coli), Aluminum Adjuvant
- Where
- 4 sites in China
- Volunteers
- 9,300 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Human Papillomavirus Infection
A Study to Evaluate the Immunogenicity and Safety of HPV Vaccine in Healthy Female Participants Aged 9-26 Years in China
The study is to evaluate immune response induced by 9-valent HPV study vaccine is non-inferior to those induced by GARDASIL® 9 administrated with 3-dose schedule in female participants aged 20-26 years in China, if the immune…
- Trial name
- NCT05662020
- Testing
- Recombinant Nonavalent (types 6/11/16/18/31/33/45/52/58) Human Papillomavirus (HPV) Vaccine (Escherichia coli), GARDASIL® 9
- Where
- China
- Volunteers
- 2,750 people, healthy volunteers welcome
- Sponsor
- Beijing Health Guard Biotechnology, Inc
Recurrent Urinary Tract Infections
Bacterial Interference for Preventing Recurrent Urinary Tract Infection - New Ways of Treatment
Urinary tract infection (UTI) is one of the most common bacterial infections worldwide. It affects 150 million people annually. Treatment of patients with UTI entails a high consumption of antibiotics and large social and health…
- Trial name
- BIrUTI (NCT04846803)
- Testing
- ABU bladder lavage, Saline bladder lavage
- Where
- 2 sites in Denmark
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Odense University Hospital
Gram-negative Bacteremia
Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial
The Gram-negative bloodstream infection Oral Antibiotic Therapy trial (The GOAT Trial) is a multi-center, randomized clinical trial that hypothesizes that early transition to oral antibiotic therapy for the treatment of…
- Trial name
- GOAT (NCT06080698)
- Testing
- Intravenous Antibiotics, Oral Antibiotics
- Where
- 11 sites in United States
- Volunteers
- 1,030 people
- Sponsor
- Johns Hopkins University
Carriage of ESBL-positive Escherichia Coli, Carriage of ESBL-positive Klebsiella Pneumoniae
Extended Tricyle Project Indonesia for Extended-spectrum Beta-lactamase Positive Klebsiella Pneumoniae and Escherichia Coli
In 2019, Indonesia's first WHO Tricycle Project revealed alarming rates of extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli across various sectors. The study found ESBL-producing E.
- Trial name
- E-Trike (NCT07106944)
- Testing
- Community pregnant women: rectal and throat swab
- Volunteers
- 100 people
- Sponsor
- Erasmus Medical Center
P. Aeruginosa, Baumannii
An Open Clinical Trial of the Safety and Efficacy of the Drug Fluorothiazinone, 300 Mg Tablets with the Participation of Adult Patients with Chronic Bacterial Cystitis"
This study is designed to evaluate the safety, clinical efficacy and antibacterial activity of the drug Fluorothiazinone, 300 mg tablets, (Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the…
- Conditions
- P. Aeruginosa, Baumannii, Klebsiella Pneumonia, E.coli Infections
- Trial name
- NCT06815549
- Testing
- Fluorothiazinone, tablets 300 mg, Nitrofurantoin 100 MG
- Volunteers
- 280 people
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Febrile Urinary Tract Infection
Pivmecillinam as Oral Step-Down Treatment for Escherichia Coli Febrile Urinary Tract Infection Versus Standard of Care
The goal of this clinical trial is to learn if oral treatment with pivmecillinam is effective to treat febrile urinary tract infections in adult patients.
- Trial name
- PIVOT (NCT07236944)
- Testing
- Pivmecillinam, Standard of Care (Investigator Choice)
- Where
- 13 sites in Norway, Sweden
- Volunteers
- 560 people
- Sponsor
- Uppsala University
Urinary Tract Infections
A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)
This is a Phase 2 superiority study of LBP-EC01, a recombinant bacteriophage cocktail, with an initial open-label 3-arm pharmacokinetic (PK) lead-in portion of 30 patients to evaluate the optimal dosing regimen to be used in the…
- Trial name
- ELIMINATE (NCT05488340)
- Testing
- LBP-EC01 0.1 x IV dose, LBP-EC01 0.01x IV Dose, LBP-EC01 IV Infusion Dose
- Where
- 17 sites in United States
- Volunteers
- 318 people
- Sponsor
- Locus Biosciences
Urinary Tract Infections
Comparative Study of the Genomic Characteristics of Uropathogenic Escherichia Coli According to the Severity of Community-Acquired Urinary Tract Infections in Guadeloupe (COLIGENURI)
The aim is to identify genomic determinants (genes or gene clusters) associated with the severity of community-acquired E. coli urinary tract infections in Guadeloupe through a comparative approach integrating clinical…
- Trial name
- COLIGENURI (NCT07905638)
- Testing
- Whole-genome sequencing (WGS) of E. coli isolates (applies to all 3 groups)
- Volunteers
- 210 people
- Sponsor
- Centre Hospitalier Universitaire de la Guadeloupe
CF - Cystic Fibrosis, Klebsiella Pneumoniae Infection
Safety of Combined Intravenous Antibiotic and Bacteriophage Therapy in Adults With Cystic Fibrosis and Antibiotic-Resistant Lung Infections
This is a Phase 1, open-label, multi-center pilot study evaluating the safety and microbiological activity of intravenous (IV) bacteriophage therapy in combination with standard IV antibiotics in adults with cystic fibrosis (CF)…
- Conditions
- CF - Cystic Fibrosis, Klebsiella Pneumoniae Infection, E Coli Infections, Staphylococcus Aureus Infection
- Trial name
- NCT07280598
- Testing
- Intravenous Bacteriophage Cocktail plus Standard IV Antibiotics
- Volunteers
- 30 people
- Sponsor
- University of California, San Diego
Urinary Tract Infections, Patients With Suprabubic Catheter
Study of E. Coli Isolates From Recurrent Urinary Tract Infections
Prospective study aiming at collecting clinical Escherichia coli isolates from patients with recurrent urinary tract infection; samples to be collected during routine procedures.
- Conditions
- Urinary Tract Infections, Patients With Suprabubic Catheter, Patients With Nephrostomy Catheter
- Trial name
- Per-UTI (NCT05826067)
- Testing
- collection of bacterial strains
- Where
- Belgium
- Volunteers
- 45 people
- Sponsor
- Université Catholique de Louvain
Cervical Cancer, Condylomata Acuminata
An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old
This is a open label clinical trial to evaluate the safety and immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) manufactured by Xiamen Innovax Biotech CO., Ltd., in…
- Trial name
- NCT05056402
- Testing
- 3 doses of the Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli), 2 doses of theRecombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58 )Vaccine(E.Coli)
- Where
- China
- Volunteers
- 1,382 people, healthy volunteers welcome
- Sponsor
- Xiamen University
Bacteriuria, Spinal Cord Injuries
Bacteriophage Therapy in Spinal Cord Injury Patients With Bacteriuria
This is a Phase 1b study to assess the safety, tolerability, PK, and PD of investigational phage therapy (IP) in adults with SCI and bladder colonization (ASB).
- Conditions
- Bacteriuria, Spinal Cord Injuries, Asymptomatic Bacteriuria, Escherichia Coli
- Trial name
- Phage (NCT06559618)
- Testing
- Phage Therapy
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Barbara Trautner
E Coli Infection, ESBL Producing E.Coli
Cefotetan Therapy for Escherichia Coli Infections
This pilot study will compare clinical outcomes among patients treated with cefotetan versus standard of care antibiotics for bacteremia caused by E. coli.
- Trial name
- NCT07318584
- Testing
- Cefotetan, Carbapenems, Beta Lactam Antibiotics
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Oregon Health and Science University